


# Claims

1. A compound of the formula,



wherein

10  $R^1$  is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;


$R^2$  is hydrogen or methyl;

$R^3$  is hydrogen or hydroxy;

15 or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1, wherein  $R^1$  is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, or (L)-ornityl-(D)-ornitylamino.
3. The compound according to Claim 1, wherein  $R^2$  and  $R^3$  are hydrogen.
4. The compound according to Claim 1, wherein  $R^1$  is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, and  $R^2$  and  $R^3$  are hydrogen.

5. The compound according to Claim 1, wherein R<sup>1</sup> is (L)-ornityl-(D)-ornitylamino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
6. The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
7. The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
8. The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
9. The compound according to Claim 1, wherein R<sup>1</sup> is N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
10. The compound according to Claim 1 wherein R<sup>2</sup> is methyl and R<sup>3</sup> is hydrogen.
11. The compound according to Claim 1 wherein R<sup>2</sup> is hydrogen and R<sup>3</sup> is hydroxyl.
12. A pharmaceutical composition comprising a mixture of a pharmaceutically acceptable carrier and an effective amount of a compound of the formula



wherein


R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

- 5 13. A method for the prophylactic and/or therapeutic treatment of mycoses which comprises administering to a human being or an animal an effective amount of the compound of the formula



wherein

10 R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or hydroxy;

15 or a pharmaceutically acceptable salt thereof.

\*\*\*